Circa 2019 o.o
A new invention uses magnets to record computer data which consume virtually zero energy, solving the dilemma of how to create faster data processing speeds without high energy costs.
Circa 2019 o.o
A new invention uses magnets to record computer data which consume virtually zero energy, solving the dilemma of how to create faster data processing speeds without high energy costs.
Adding hypersonic missiles to the arsenal of dozens of Arleigh Burke class destroyers could be a very expensive and labor intensive endeavor.
The Navy is exploring new options for replenishing its submarines out at sea, which could have broader impacts on how it resupplies all of its fleets.
Someone from Oxford’s vaccine trial has passed away.
BRAZIL’S health authority has confirmed a volunteer has died after participating in the clinical trials of the coronavirus vaccine developed by AstraZeneca and Oxford University.
He built a rollercoaster in his backyard.
This guy built a fully functional rollercoaster in his backyard 😱 🎢.
Self healing material is being developed for prosthetic limbs.
This material can help us make self-healing prosthetic limbs in the future.
OneSkin Technologies is a longevity company started by a team of incredible female PHDs and entrepreneurs, who have been using cutting edge technology to identify the senescent cells that cause your skin to age.
⠀⠀⠀
Discover how they use key peptide molecules to eliminate those senescent cells, making you look and feel 10 years younger.
Subscribe for Peter’s latest tech insights & updates: https://www.diamandis.com/subscribe
Using the Crispr gene-editing technique that won a recent Nobel Prize, Crispr Therapeutics cleared blood cancers in patients with off-the-shelf immune cells. These so-called CAR-T therapies previously required a patient’s own cells.
In a Wednesday morning announcement, Crispr Therapeutics (ticker: CRSP) said that its gene-editing let doctors use cells from healthy donors—opening up prospects for broadly available, less-expensive use of CAR-T treatment.
In the Phase 1 trial, the lymphoma blood cancer in four of 11 patients responded completely to infusions of T cells whose genes were altered to target the cancer and prevent transplant rejection. Standard treatments had failed all participants. In patients that got higher doses, the complete responses have lasted for months.